Thymectomy in late-onset myasthenia gravis

Area of Science:

• Neurology
• Immunology
• Surgical Oncology

Background:

• Myasthenia gravis (MG) is a chronic autoimmune neuromuscular disease.
• Late-onset MG (over 55 years) presents unique management challenges.
• The role of thymectomy in older MG patients remains debated.

Purpose of the Study:

• To evaluate the safety and efficacy of thymectomy in patients over 55 with myasthenia gravis.
• To assess the necessity of long-term immunosuppressive therapy post-thymectomy.
• To correlate clinical outcomes with acetylcholine-receptor antibody titers and thymus gland status.

Main Methods:

• A cohort of 12 consecutive myasthenia gravis patients (age > 55) underwent thymectomy between 1977-1979.
• Clinical outcomes, medication requirements, and acetylcholine-receptor antibody titers were monitored.
• Thymus gland pathology (atrophy) was assessed.

Main Results:

• All 12 patients experienced clinical improvement following thymectomy.
• 11 patients achieved remission from generalized myasthenia gravis symptoms.
• Nine patients discontinued all MG medications; antibody titers showed no significant change.
• Clinical improvement occurred even in patients with atrophic thymus glands.

Conclusions:

• Thymectomy is a safe and effective treatment for late-onset myasthenia gravis in patients over 55.
• Steroids and anticholinesterase agents may not be essential for managing this patient group.
• Clinical response to thymectomy is not dependent on reduction of acetylcholine-receptor antibody titers or thymus gland size.